Kingsview Wealth Management LLC purchased a new stake in Edwards Lifesciences Corporation (NYSE:EW – Free Report) in the second quarter, HoldingsChannel reports. The firm purchased 24,532 shares of the medical research company’s stock, valued at approximately $2,219,000.
Other institutional investors have also recently bought and sold shares of the company. Hanson & Doremus Investment Management acquired a new position in Edwards Lifesciences during the 1st quarter worth $25,000. JPL Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at $25,000. MV Capital Management Inc. bought a new stake in shares of Edwards Lifesciences during the fourth quarter worth $26,000. RMG Wealth Management LLC bought a new stake in shares of Edwards Lifesciences during the first quarter worth $26,000. Finally, Pin Oak Investment Advisors Inc. acquired a new position in shares of Edwards Lifesciences during the second quarter valued at $26,000. Institutional investors own 79.46% of the company’s stock.
Edwards Lifesciences Trading Up 0.3%
NYSE EW opened at $90.19 on Friday. The stock has a 50-day simple moving average of $89.54 and a 200 day simple moving average of $85.03. The company has a market capitalization of $51.93 billion, a PE ratio of 51.83, a P/E/G ratio of 2.37 and a beta of 0.85. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $96.29.
Insider Buying and Selling
In related news, VP Daniel J. Lippis sold 619 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the transaction, the vice president owned 40,034 shares of the company’s stock, valued at $3,684,329.02. This trade represents a 1.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Annette Bruls sold 2,644 shares of the business’s stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $89.98, for a total transaction of $237,907.12. Following the transaction, the vice president owned 17,984 shares of the company’s stock, valued at approximately $1,618,200.32. This represents a 12.82% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 4,501 shares of company stock worth $408,213 over the last quarter. 0.31% of the stock is currently owned by corporate insiders.
Wall Street Analysts Forecast Growth
Several equities analysts recently issued reports on EW shares. Piper Sandler reiterated an “overweight” rating and issued a $101.00 price target (up from $100.00) on shares of Edwards Lifesciences in a report on Friday, July 24th. Evercore restated an “outperform” rating and set a $100.00 target price on shares of Edwards Lifesciences in a research report on Monday, July 6th. TD Cowen reaffirmed a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. BTIG Research lifted their price target on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Finally, Wall Street Zen downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Seventeen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average price target of $100.27.
View Our Latest Stock Report on EW
Edwards Lifesciences Company Profile
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Read More
- Five stocks we like better than Edwards Lifesciences
- From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
- These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW – Free Report).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
